MedTrace Logo

Bioavailability of Resveratrol From Vineatrol30 Extract Incorporated Into Micelles

NCT02944097 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2017-05-03

No results posted yet for this study

Summary

To enhance the oral bioavailability of the antioxidants trans-resveratrol and trans-ε-viniferin from Vineatrol30 grapevine-shoot extract, the native powder was incorporated into micelles. A single dose, single blind, two arms crossover trial was conducted. Plasma and urine samples were collected at intervals up to 24 h after oral intake of native or micellar Vineatrol30 (500 mg), and resveratrol content was quantified and compared between formulations. Tolerability of the dose was also controlled by safety parameters in plasma.

Conditions

  • Safety After Oral Intake
  • Pharmacokinetics After Oral Intake

Interventions

DIETARY_SUPPLEMENT

Vineatrol 30 native powder

DIETARY_SUPPLEMENT

Vineatrol 30 micelles

Sponsors & Collaborators

  • University of Hohenheim

    lead OTHER

Principal Investigators

  • Jan Frank, Prof. Dr · University of Hohenheim

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
35 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-03-31
Primary Completion
2015-05-31
Completion
2017-02-28

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02944097 on ClinicalTrials.gov